At a glance
- Originator Bayer Schering Pharma
- Class Anti-ischaemics; Anticoagulants; Antihypertensives; Antiplatelets; Prostaglandins
- Mechanism of Action Prostaglandin D agonists; Prostaglandin D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypertension; Ischaemic heart disorders; Thrombosis
Most Recent Events
- 15 Jun 2004 Discontinued - Preclinical for Hypertension in Germany (unspecified route)
- 15 Jun 2004 Discontinued - Preclinical for Ischaemic heart disorders in Germany (unspecified route)
- 15 Jun 2004 Discontinued - Preclinical for Thrombosis in Germany (unspecified route)